Related references
Note: Only part of the references are listed.Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy
Valeria Barbosa de Souza et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
Role of STAT3 signaling pathway in breast cancer
Jia-hui Ma et al.
CELL COMMUNICATION AND SIGNALING (2020)
Pharmacokinetics and metabolism of ulixertinib in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry
Bin Yu et al.
JOURNAL OF SEPARATION SCIENCE (2020)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens
Peter Larsson et al.
SCIENTIFIC REPORTS (2020)
Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells
Ewa Jasek-Gajda et al.
CANCER GENOMICS & PROTEOMICS (2020)
Targeting Alterations in the RAF-MEK Pathway
Rona Yaeger et al.
CANCER DISCOVERY (2019)
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
Debasis Das et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Direct Ras G12C inhibitors: crossing the rubicon
Colin R. Lindsay et al.
BRITISH JOURNAL OF CANCER (2019)
Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease
Peterson de Andrade et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan et al.
CANCER DISCOVERY (2018)
Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure
Daniel Fabio Kawano et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
Jaquelyn N. Sanchez et al.
DRUGS (2018)
Anti-cancer activity of a new dihydropyridine derivative, VdiE-2N, in head and neck squamous cell carcinoma
Renata Nishida Goto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Kinase inhibitors: the road ahead
Fleur M. Ferguson et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Andrew M. Kidger et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Zahra Hosseinzadeh et al.
CURRENT ORGANIC CHEMISTRY (2018)
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Stergios J. Moschos et al.
JCI INSIGHT (2018)
Identification of a novel putative inhibitor of the Plasmodium falciparum purine nucleoside phosphorylase: exploring the purine salvage pathway to design new antimalarial drugs
Luciano Porto Kagami et al.
MOLECULAR DIVERSITY (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation
Graham F. Smith et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification
Saulo Fehelberg Pinto Braga et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Copper Acetate Catalyzed Regioselective Synthesis of Substituted 1,2,3-Triazoles: A Versatile Azide-Alkene Cycloaddition/Oxidation Approach
Sandeep Rohilla et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2016)
The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model
Jeanette Birnbaum et al.
ANNALS OF INTERNAL MEDICINE (2016)
Novel hederagenin-triazolyl derivatives as potential anti-cancer agents
Diego Rodriguez-Hernandez et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
The kinome 'at large' in cancer
Emmy D. G. Fleuren et al.
NATURE REVIEWS CANCER (2016)
Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors
Daniel J. Burdick et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Ten things you should know about protein kinases: IUPHAR Review 14
Doriano Fabbro et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Playing Polo-Like Kinase in NRAS-Mutant Melanoma
Hsin-Yi Chen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells
Jin Mo Ku et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2015)
Discovery of substituted 4-aminoquinazolines as selective Toll-like receptor 4 ligands
Afshin Nour et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Synthesis and Structure-Activity Relationship Studies of Conformationally Flexible Tetrahydroisoquinolinyl Triazole Carboxamide and Triazole Substituted Benzamide Analogues as σ2 Receptor Ligands
Suping Bai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The clinical development of MEK inhibitors
Yujie Zhao et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance
Phillip A. Schwartz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA
Serena Marchetti et al.
INVESTIGATIONAL NEW DRUGS (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Amination of Benzoxazoles and 1,3,4-Oxadiazoles Using 2,2,6,6-Tetramethylpiperidine-N-oxoammonium Tetrafluoroborate as an Organic Oxidant
Sebastian Wertz et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
A. Azzariti et al.
BRITISH JOURNAL OF CANCER (2011)
Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors
Cunlong Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia
Christopher J. Helal et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2
John J. Caldwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Design, Synthesis, and Structure-Affinity Relationships of Regioisomeric N-Benzyl Alkyl Ether Piperazine Derivatives as σ-1 Receptor Ligands
Iman A. Moussa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Characterization of Tunable Piperidine and Piperazine Carbamates as Inhibitors of Endocannabinoid Hydrolases
Jonathan Z. Long et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Application of copper(I)-catalysed azide/alkyne cycloaddition (CuAAC) 'click chemistry' in carbohydrate drug and neoglycopolymer synthesis
Valquiria Aragao-Leoneti et al.
TETRAHEDRON (2010)
PoseView -- molecular interaction patterns at a glance
Katrin Stierand et al.
Journal of Cheminformatics (2010)
Synthesis and in vitro antitubercular activity of a series of quinoline derivatives
Marcus V. N. de Souza et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F
Xiang S. Wang et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2008)
One-pot reductive cyclization to antitumor quinazoline precursors
Sandip K. Kundu et al.
ARKIVOC (2008)
Lessons in molecular recognition. 2. Assessing and improving cross-docking accuracy
Jeffrey J. Sutherland et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)
ERK implication in cell cycle regulation
Jean-Claude Chambard et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis
Robert W. Wilkinson et al.
CLINICAL CANCER RESEARCH (2007)
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
S. Meloche et al.
ONCOGENE (2007)
Continuous ERK activation downregulates anti proliferative genes throughout G1 phase to allow cell-cycle progression
Takuya Yamamoto et al.
CURRENT BIOLOGY (2006)
An efficient direct amination of cyclic amides and cyclic ureas
Zhao-Kui Wan et al.
ORGANIC LETTERS (2006)
Co-prescription of cytochromeP450 2D6/3A4 inhibitor-substrate pairs in clinical practice.: A retrospective analysis of data from Norwegian primary pharmacies
E Molden et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
RA Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
A potent and highly selective inhibitor of human α-1,3-fucosyltransferase via click chemistry
LV Lee et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Microwave-assisted Niementowski reaction. Back to the roots
FR Alexandre et al.
TETRAHEDRON LETTERS (2002)
Share Paper
